PMID- 30241151
OWN - NLM
STAT- MEDLINE
DCOM- 20191030
LR  - 20191030
IS  - 2378-9506 (Electronic)
IS  - 2378-9506 (Linking)
VI  - 4
DP  - 2018 Sep
TI  - Impact of Geographic Regions on Overall Survival in Patients With Metastatic 
      Renal Cell Carcinoma: Results From an International Clinical Trials Database.
PG  - 1-14
LID - 10.1200/JGO.17.00119 [doi]
LID - JGO.17.00119
AB  - PURPOSE: Health determinants vary according to geographic region and may affect 
      the outcomes of patients with metastatic renal cell carcinoma (mRCC) treated 
      during clinical trials of targeted therapy. Here, we investigate the overall 
      survival (OS) of patients with mRCC treated in the era of targeted therapy by 
      geographic region. METHODS: We conducted a pooled analysis of patients with mRCC 
      who were treated during phase II or III clinical trials. Clinical characteristics 
      and survival data were collected. Statistical analyses were performed with the 
      Kaplan-Meier method and log-rank test in univariable analysis. RESULTS: Overall, 
      4,736 patients were included in the analysis. Patient characteristics differed 
      according to geographic region. No statistically significant differences in OS 
      were observed when the United States/Canada (USC) was compared with the following 
      other regions: Latin America, Asia/Oceania/Africa, and Eastern Europe. In a 
      univariable analysis, OS differed among patients enrolled in trials in USC 
      compared with Western Europe (20.3 v 17.4 months; hazard ratio, 1.15; 95% CI, 
      1.03 to 1.3; P = .015), but it did not differ in a multivariable analysis. 
      All-grade treatment-related adverse events (AEs) were observed more frequently in 
      USC. There were no significant differences in grade 3 to 5 AEs among groups. 
      CONCLUSION: Despite different baseline characteristics, OS was similar among 
      patients enrolled in clinical trials across different geographic regions. Access 
      to clinical trials as well as disease biology, AE reporting, and quality of care 
      may contribute to potential differences in outcomes.
FAU - Fay, Andre P
AU  - Fay AP
AD  - Andre P. Fay, Hospital Sao Lucas/Pontificia Universidade Catolica do Rio Grande 
      do Sul, Porto Alegre, Brazil; Rana R. McKay, University of California San Diego, 
      San Diego, CA; Xun Lin and Ronit Simantov, Pfizer Oncology, New York, NY; and 
      Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.
FAU - McKay, Rana R
AU  - McKay RR
AD  - Andre P. Fay, Hospital Sao Lucas/Pontificia Universidade Catolica do Rio Grande 
      do Sul, Porto Alegre, Brazil; Rana R. McKay, University of California San Diego, 
      San Diego, CA; Xun Lin and Ronit Simantov, Pfizer Oncology, New York, NY; and 
      Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.
FAU - Lin, Xun
AU  - Lin X
AD  - Andre P. Fay, Hospital Sao Lucas/Pontificia Universidade Catolica do Rio Grande 
      do Sul, Porto Alegre, Brazil; Rana R. McKay, University of California San Diego, 
      San Diego, CA; Xun Lin and Ronit Simantov, Pfizer Oncology, New York, NY; and 
      Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.
FAU - Simantov, Ronit
AU  - Simantov R
AD  - Andre P. Fay, Hospital Sao Lucas/Pontificia Universidade Catolica do Rio Grande 
      do Sul, Porto Alegre, Brazil; Rana R. McKay, University of California San Diego, 
      San Diego, CA; Xun Lin and Ronit Simantov, Pfizer Oncology, New York, NY; and 
      Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.
FAU - Choueiri, Toni K
AU  - Choueiri TK
AD  - Andre P. Fay, Hospital Sao Lucas/Pontificia Universidade Catolica do Rio Grande 
      do Sul, Porto Alegre, Brazil; Rana R. McKay, University of California San Diego, 
      San Diego, CA; Xun Lin and Ronit Simantov, Pfizer Oncology, New York, NY; and 
      Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Glob Oncol
JT  - Journal of global oncology
JID - 101674751
SB  - IM
MH  - Carcinoma, Renal Cell/*epidemiology/mortality
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*epidemiology/mortality
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Treatment Outcome
PMC - PMC6223429
EDAT- 2018/09/23 06:00
MHDA- 2019/10/31 06:00
PMCR- 2018/01/11
CRDT- 2018/09/23 06:00
PHST- 2018/09/23 06:00 [entrez]
PHST- 2018/09/23 06:00 [pubmed]
PHST- 2019/10/31 06:00 [medline]
PHST- 2018/01/11 00:00 [pmc-release]
AID - 1700119 [pii]
AID - 10.1200/JGO.17.00119 [doi]
PST - ppublish
SO  - J Glob Oncol. 2018 Sep;4:1-14. doi: 10.1200/JGO.17.00119.